⏳ Fetching live dividend data...
Home › Calculator › ICAD Dividend Calculator 2026
iCAD, Inc. · NASDAQ
Price: $3.87 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ICAD → $2183500999.74M in 10 years · $181,615,227,713,652.80/month
iCAD, Inc. specializes in delivering advanced solutions for cancer management, encompassing sophisticated image analysis tools, streamlined workflow optimization, and targeted radiation therapy. While primarily operating in the United States, the company also maintains a significant international presence. Its operations are organized into two principal divisions: Cancer Detection and Cancer Therapy. In the Cancer Detection segment, iCAD provides a range of innovative technologies. This includes the PowerLook platform, which serves as a central host for artificial intelligence algorithms and facilitates seamless communication between imaging acquisition devices, storage systems, and review platforms. Key diagnostic offerings feature SecondLook, a machine learning-driven algorithm designed to examine 2D full-field digital mammography images for identifying and marking suspicious masses and calcifications. Additionally, the company offers automated solutions for consistent and standardized assessment of breast density. Its portfolio further extends to ProFound AI, a deep-learning algorithm adept at detecting malignant soft-tissue densities and calcifications within digital breast tomosynthesis, and ProFound AI Risk, a tool that provides breast cancer risk estimation derived from screening mammograms. Magnetic resonance imaging (MRI) applications are also available for detecting breast and prostate cancer, along with VeraLook, a solution supporting the identification of colonic polyps in conjunction with CT Colonography. The Cancer Therapy division features the Xoft Axxent electronic brachytherapy systems. These systems are employed in the treatment of early-stage breast, non-melanoma skin, and gynecological cancers. Their clientele is diverse, spanning university research centers, community hospitals, specialized cancer care clinics, veterinary facilities, and dermatology practices. iCAD distributes its products through multiple channels, utilizing its own direct sales organizations, as well as collaborating with original equipment manufacturer (OEM) partners, various distributors, technology platform partners, and resellers. The company also has a global footprint, exporting its advanced technologies to regions including Europe, Taiwan, Canada, China, and other international markets. Originally established in 1984 under the name Howtek, Inc., the company was rebranded as iCAD, Inc. in June 2002. Its corporate headquarters are located in Nashua, New Hampshire.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ICAD position with:
Real after-tax yield depends on where you live and how you hold ICAD.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 51.68% | 48.88% | $5,168 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 43.93% | 41.13% | $4,393 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 41.34% | 38.54% | $4,134 / yr |
| 🇬🇧 UK ISA | 0% | 51.68% | 48.88% | $5,168 / yr |
| 🇬🇧 UK Taxable | 8.75% | 47.16% | 44.36% | $4,716 / yr |
| 🇨🇦 TFSA | 0% | 51.68% | 48.88% | $5,168 / yr |
| 🇨🇦 CA Taxable | 25% | 38.76% | 35.96% | $3,876 / yr |
| 🇦🇺 Super (pension) | 15% | 43.93% | 41.13% | $4,393 / yr |
| 🇦🇺 AU Taxable | 30% | 36.18% | 33.38% | $3,618 / yr |
| 🇩🇪 DE Taxable | 26.375% | 38.05% | 35.25% | $3,805 / yr |
| 🇫🇷 FR Taxable | 30% | 36.18% | 33.38% | $3,618 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ICAD pays quarterly — 4 times per year. Next ex-div: TBD.
How ICAD compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ICAD sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-07-17 | 40,000 | $1.36 | $54.4K | ||
| D-Return | 2025-07-17 | 6,641 | $3.69 | $24.5K | ||
| D-Return | 2025-07-17 | 5,415 | $1.52 | $8.2K | ||
| D-Return | 2025-07-17 | 30,000 | $2.06 | $61.8K | ||
| D-Return | 2025-07-17 | 25,000 | $4.37 | $109.3K | ||
| D-Return | 2025-07-17 | 14,183 | $12.84 | $182.1K | ||
| D-Return | 2025-07-17 | 19,000 | $18.00 | $342.0K | ||
| D-Return | 2025-07-17 | 25,000 | $4.25 | $106.3K | ||
| D-Return | 2025-07-17 | 50,000 | $1.85 | $92.5K | ||
| D-Return | 2025-07-17 | 188,725 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ICAD dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
iCAD, Inc. (ICAD) is currently trading at $3.87, 81% below its 52-week high. The current dividend yield is 51.68% based on an annual payout of $2.00 per share.
iCAD, Inc. (ICAD) is a healthcare stock currently trading at $3.87 with a dividend yield of 51.68%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →